NASDAQ:RLAY Relay Therapeutics Q3 2024 Earnings Report $18.60 +0.41 (+2.25%) As of 10:57 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Relay Therapeutics EPS ResultsActual EPS-$0.63Consensus EPS -$0.77Beat/MissBeat by +$0.14One Year Ago EPS-$0.54Relay Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$0.09 millionBeat/MissN/AYoY Revenue Growth-100.00%Relay Therapeutics Announcement DetailsQuarterQ3 2024Date11/6/2024TimeAfter Market ClosesConference Call DateWednesday, November 6, 2024Conference Call Time4:00PM ETUpcoming EarningsRelay Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Relay Therapeutics Earnings HeadlinesHead to Head Survey: Relay Therapeutics (NASDAQ:RLAY) and I-Mab (NASDAQ:NBP)September 22 at 5:14 AM | americanbankingnews.comRelay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comWATCH THIS BEFORE SEPTEMBER 25TH!!James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has noticed it. Altucher believes the filing could matter to as many as 1,806,000 Americans in the years ahead. He explains why Musk buried it and what it could mean, free of charge.September 22 at 1:00 AM | Paradigm Press (Ad)Monte Rosa Therapeutics (NASDAQ:GLUE) versus Relay Therapeutics (NASDAQ:RLAY) Financial ComparisonSeptember 12, 2026 | americanbankingnews.comRelay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks TranscriptSeptember 10, 2026 | seekingalpha.comRelay Therapeutics CFO Sells 17,717 Shares for $350,000September 2, 2026 | fool.comSee More Relay Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Relay Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Relay Therapeutics and other key companies, straight to your email. Email Address About Relay TherapeuticsRelay Therapeutics (NASDAQ:RLAY) is a clinical-stage biotechnology company that develops medicines for patients with genetically defined diseases, including cancer. The company combines computational and experimental approaches to study how proteins move and change shape, with the goal of identifying druggable sites and designing more selective therapies. Relay’s research platform, known as Dynamo, integrates structural biology, computational modeling, biophysics and chemistry to support the discovery and development of small-molecule drug candidates. Its pipeline has included targeted oncology programs such as RLY-2608, an investigational, mutation-selective PI3Kα inhibitor, and RLY-4008, an investigational FGFR2 inhibitor designed to selectively target alterations in the FGFR2 gene. Founded in 2016 and headquartered in Cambridge, Massachusetts, Relay Therapeutics operates as a research and development company serving the global biopharmaceutical market. Its programs are generally advanced through clinical development and potential commercialization through internal efforts and strategic collaborations. Sanjiv Patel has served as the company’s president and chief executive officer.View Relay Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nucor and Steel Dynamics Just Pulled Back—The Steel Story Still Looks Strong5 Dividend Stocks That Combine Income, Earnings Growth, and Wall Street SupportDespite Record Sales, Texas Roadhouse Has Beef With Beef CostsEncore Capital Group Has Doubled—But Its Best Tailwind Won’t Last ForeverCoach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One3 Surging Stocks That Don’t Need the AI Boom to Keep Winning Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
